Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Cash & Equivalents: 2022-2024

Historic Cash & Equivalents for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Dec 2024 value amounting to $56.8 million.

  • Orchestra BioMed Holdings' Cash & Equivalents rose 35.56% to $74.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.0 million, marking a year-over-year increase of 35.56%. This contributed to the annual value of $56.8 million for FY2024, which is 32.88% down from last year.
  • According to the latest figures from FY2024, Orchestra BioMed Holdings' Cash & Equivalents is $56.8 million, which was down 32.88% from $84.6 million recorded in FY2023.
  • In the past 5 years, Orchestra BioMed Holdings' Cash & Equivalents ranged from a high of $84.6 million in FY2023 and a low of $56.8 million during FY2024.
  • For the 3-year period, Orchestra BioMed Holdings' Cash & Equivalents averaged around $74.7 million, with its median value being $82.6 million (2022).
  • In the last 5 years, Orchestra BioMed Holdings' Cash & Equivalents increased by 2.50% in 2023 and then plummeted by 32.88% in 2024.
  • Orchestra BioMed Holdings' Cash & Equivalents (Yearly) stood at $82.6 million in 2022, then climbed by 2.50% to $84.6 million in 2023, then slumped by 32.88% to $56.8 million in 2024.